Literature DB >> 746428

The effect of thyrocalcitonin therapy and phosphate deprivation on tumoral calcinosis.

J C Kallmeyer, L P Seimon, E T MacSearraigh.   

Abstract

Six siblings were screened for clinical and biochemical evidence of tumoral calcinosis. The 3 brothers showed all the characteristic manifestations of this entity. Two of them were treated for an initial period of 6 months with large doses of thyrocalcitonin, with virtually no response. After a 9-month equilibration period they were treated by phosphate depletion, and at the end of 6 months they were re-investigated. There was no appreciable objective or radiological difference in the extent of the masses. It was concluded that, in these 2 patients, surgical excision of the tumours was the only feasible form of therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 746428

Source DB:  PubMed          Journal:  S Afr Med J


  6 in total

Review 1.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

Review 2.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

Review 3.  Review of tumoral calcinosis: A rare clinico-pathological entity.

Authors:  Ibrahim Fathi; Mahmoud Sakr
Journal:  World J Clin Cases       Date:  2014-09-16       Impact factor: 1.337

4.  A rare case report of tumoral calcinosis syndrome in an adult with rheumatoid arthritis.

Authors:  Hiren Patel; Hamid Shaaban; Howard Benn
Journal:  Clin Cases Miner Bone Metab       Date:  2015 Jan-Apr

Review 5.  Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.

Authors:  Lisal J Folsom; Erik A Imel
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 6.  Tumoral calcinosis: case report and review.

Authors:  A F Bishop; J M Destouet; W A Murphy; L A Gilula
Journal:  Skeletal Radiol       Date:  1982       Impact factor: 2.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.